Voyager Therapeutics (VYGR) Current Deferred Revenue (2014 - 2026)

Voyager Therapeutics (VYGR) has 13 years of Current Deferred Revenue data on file, last reported at $395000.0 in Q1 2026.

• For the quarter ending Q1 2026, Current Deferred Revenue fell 98.13% year-over-year to $395000.0; the trailing twelve-month figure through Mar 2026 stood at $395000.0 (down 98.13% YoY), and the FY2025 full-year result was $1.6 million, down 93.48% from the prior year.
• Current Deferred Revenue fell to $395000.0 in Q1 2026, from $1.6 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $87.0 million in Q2 2022 to a low of $395000.0 in Q1 2026.
• A 5-year average of $34.6 million and a median of $24.4 million in 2024 frame the typical range for Current Deferred Revenue.
• Across the five-year window, Current Deferred Revenue jumped 978.24% in 2022 and plunged 98.13% in 2026, its largest moves.
• Tracing VYGR's Current Deferred Revenue over 5 years: stood at $59.4 million in 2022, then dropped by 27.78% to $42.9 million in 2023, then plunged by 43.11% to $24.4 million in 2024, then tumbled by 93.48% to $1.6 million in 2025, then tumbled by 75.16% to $395000.0 in 2026.
• Business Quant data shows VYGR's Current Deferred Revenue at $395000.0 in Q1 2026, $1.6 million in Q4 2025, and $10.6 million in Q3 2025.